IL17A and COVID-19: In asthma, there were variations in ACE2 expression due to different asthma endotypes which can influence COVID-19 susceptibility, with IL-17 potentially upregulating ACE2 expression, while IL-4 and IL-13 may downregulate it [25, 26].